Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Wilson

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorSauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Cancer Discovery|September 25, 2012
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitorVito Guagnano, Audrey Kauffmann, Simon Wöhrle, et al.
Plos One|September 18, 2015
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Science (New York, N.Y.)|May 22, 2010
Self-assembly of Janus dendrimers into uniform dendrimersomes and other complex architecturesVirgil Percec, Daniela A Wilson, Pawaret Leowanawat, et al.
Plos One|January 6, 2016
Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Cancer Discovery|August 10, 2012
Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growthFred Harbinski, Vanessa J Craig, Sneha Sanghavi, et al.
Chemistry & Biology|July 30, 2013
PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signalingXinming Cai, Yongyao Xu, Atwood K Cheung, et al.
Journal of Medicinal Chemistry|January 21, 2020
Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS DisordersSimone Bonazzi, Carleton P Goold, Audrey Gray, et al.
Plos One|September 13, 2012
Identification of elongation factor G as the conserved cellular target of argyrin BBeat Nyfeler, Dominic Hoepfner, Deborah Palestrant, et al.
Nature Biotechnology|May 1, 2023
A highly efficient transgene knock-in technology in clinically relevant cell typesAlexander G Allen, Samia Q Khan, Carrie M Margulies, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorSauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Cancer Discovery|September 25, 2012
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitorVito Guagnano, Audrey Kauffmann, Simon Wöhrle, et al.
Plos One|September 18, 2015
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Science (New York, N.Y.)|May 22, 2010
Self-assembly of Janus dendrimers into uniform dendrimersomes and other complex architecturesVirgil Percec, Daniela A Wilson, Pawaret Leowanawat, et al.
Plos One|January 6, 2016
Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Cancer Discovery|August 10, 2012
Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growthFred Harbinski, Vanessa J Craig, Sneha Sanghavi, et al.
Chemistry & Biology|July 30, 2013
PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signalingXinming Cai, Yongyao Xu, Atwood K Cheung, et al.
Journal of Medicinal Chemistry|January 21, 2020
Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS DisordersSimone Bonazzi, Carleton P Goold, Audrey Gray, et al.
Plos One|September 13, 2012
Identification of elongation factor G as the conserved cellular target of argyrin BBeat Nyfeler, Dominic Hoepfner, Deborah Palestrant, et al.
Nature Biotechnology|May 1, 2023
A highly efficient transgene knock-in technology in clinically relevant cell typesAlexander G Allen, Samia Q Khan, Carrie M Margulies, et al.
Pageof 9